MedPath

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Registration Number
NCT01369095
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
976
Inclusion Criteria
  • Men and women of age 18-65 years (Argentina minimum age will be 24 years of age)
  • Patients must be able to understand the nature of the study, agree to comply with the prescribed dosage regimens, report for regularly scheduled office visits, and communicate to study personnel about adverse events and concomitant medication use.
  • Patients with a diagnosis of Major Depressive Disorder, currently experiencing a Major Depressive Episode, as defined by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (Text Revision)[DSM IV TR] criteria. The current depressive episode must be > 8 weeks in duration and < 3 years duration.
  • In the current Major depressive disorder (MDD) episode, patients should report a history of inadequate response to 1-3 adequate trials of antidepressant treatment.
  • Patients must have a 17-item Hamilton Depression Rating Scale (HAM-D17) total score ≥ 18 at Screening and Baseline.
Exclusion Criteria
  • Patients who report an inadequate response (less than 50% reduction in depressive symptom severity) to more than three adequate trials of antidepressant treatments during the current depressive episode.
  • Patients who have failed Duloxetine and Escitalopram at an adequate dose and for an adequate duration in their current episode.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placeboBMS-820836-
Arm 1: Duloxetine / Escitalopram + BMS-820836 placeboDuloxetine-
Arm 1: Duloxetine / Escitalopram + BMS-820836 placeboEscitalopram-
Arm 1: Duloxetine / Escitalopram + BMS-820836 placeboBMS-820836 Placebo-
Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placeboBMS-820836 Placebo-
Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placeboBMS-820836-
Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placeboBMS-820836-
Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placeboBMS-820836-
Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placeboBMS-820836 Placebo-
Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placeboBMS-820836 Placebo-
Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placeboBMS-820836 Placebo-
Primary Outcome Measures
NameTimeMethod
Change from baseline to endpoint in the Montgomery Asberg Depression Rating Scale (MADRS) total scoreWeek 13
Secondary Outcome Measures
NameTimeMethod
Change from baseline to endpoint in mean Sheehan Disability Scale (SDS) score.Week 13

Trial Locations

Locations (48)

Mclean Hospital

🇺🇸

Belmont, Massachusetts, United States

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

Pacific Clinical Research Medical Group

🇺🇸

Orange, California, United States

Insite Clinical Research

🇺🇸

Desoto, Texas, United States

Keystone Clinical Studies, Llc

🇺🇸

Norristown, Pennsylvania, United States

Amit Vijapura

🇺🇸

Jacksonville, Florida, United States

Local Institution

🇬🇧

Birmingham, West Midlands, United Kingdom

Behavioral Research Specialists, Llc

🇺🇸

Glendale, California, United States

Arkansas Psychiatric Clinic Clinical Research Trials, P.A.

🇺🇸

Little Rock, Arkansas, United States

Suburban Research Associates

🇺🇸

Media, Pennsylvania, United States

Clinco

🇺🇸

Terre Haute, Indiana, United States

Grayline Clinical Drug Trials

🇺🇸

Wichita Falls, Texas, United States

Neuropsychiatric Associates

🇺🇸

Woodstock, Vermont, United States

Future Search Trials

🇺🇸

Austin, Texas, United States

Lincoln Research

🇺🇸

Lincoln, Rhode Island, United States

Ericksen Research And Development

🇺🇸

Clinton, Utah, United States

Northcoast Clinical Trials, Inc

🇺🇸

Beachwood, Ohio, United States

Neurology & Neuroscience Center Of Ohio

🇺🇸

Toledo, Ohio, United States

Village Clinical Research, Inc.

🇺🇸

New York, New York, United States

Meridien Research

🇺🇸

Brooksville, Florida, United States

Clinical Trials Technology, Inc

🇺🇸

Prairie Village, Kansas, United States

Birmingham Psychiatry Pharmaceutical Studies, Inc.

🇺🇸

Birmingham, Alabama, United States

Artemis Institute For Clinical Research

🇺🇸

San Diego, California, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

Sharp Mesa Vista Hospital

🇺🇸

San Diego, California, United States

Connecticut Clinical Research

🇺🇸

Cromwell, Connecticut, United States

Janus Center For Psychiatric Research

🇺🇸

West Palm Beach, Florida, United States

Gulfcoast Clinical Research Center

🇺🇸

Fort Myers, Florida, United States

Uptown Research Institute, Llc

🇺🇸

Chicago, Illinois, United States

Ert

🇺🇸

Pittsburgh, Pennsylvania, United States

Comprehensive Clinical Development, Inc

🇺🇸

Fresh Meadows, New York, United States

Patient Priority Clinical Sites, Llc

🇺🇸

Cincinnati, Ohio, United States

Neuropsychiatric Research Center Of Orange County

🇺🇸

Pittsburgh, Pennsylvania, United States

Northwest Clinical Research Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Futuresearch Trials Of Dallas

🇺🇸

Dallas, Texas, United States

Ben Taub General Hospital

🇺🇸

Houston, Texas, United States

Western Affiliated Research Institute

🇺🇸

Denver, Colorado, United States

Stedman Clinical Trials

🇺🇸

Tampa, Florida, United States

Affiliated Research Institute

🇺🇸

San Diego, California, United States

Bioscience Research, Llc

🇺🇸

Mount Kisco, New York, United States

Neuroscience, Inc

🇺🇸

Herndon, Virginia, United States

Dean Foundation For Health Research & Education

🇺🇸

Middleton, Wisconsin, United States

Summit Research Network (Seattle) Llc

🇺🇸

Seattle, Washington, United States

Albuquerque Neuroscience, Inc.

🇺🇸

Albuquerque, New Mexico, United States

Catalina Research Institute, Llc

🇺🇸

Chino, California, United States

Anderson Clinical Research

🇺🇸

Redlands, California, United States

Clinical Methods Llc

🇺🇸

Murray, Utah, United States

Bio Behavioral Health

🇺🇸

Toms River, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath